DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single dose.

Experts unpack placebo and nocebo effects in psychiatry, revealing how expectation, framing, and alliance boost outcomes and curb side effects.

New primate data show IV tau-silencing gene therapy cuts brain tau up to 75% with liver-sparing safety, clearing path for 2026 trial.

Learn about screening for postpartum depression and available pharmacological treatments.

FDA accepts AXS-12 NDA for cataplexy in narcolepsy after phase 3 shows fewer attacks, better wakefulness, and cognition; decision due May 2027.

New data in cannabis use disorder show investigational drug PP-01 cuts irritability 42% in trials.

Learn how CYP450 genetics, phase 2 metabolism, and drug interactions shape psychiatric dosing—what’s actionable now and what’s next in PPGx.

ASPIRE survey reveals fatigue and cognitive impairment reduce work abilities and quality of life in narcolepsy and idiopathic hypersomnia, exposing unmet needs.

Phase 2b data show DT‑120, optimized oral LSD, delivers durable GAD remission with mostly same‑day side effects; phase 3 trials advance.